Zambia Registers New Long-Acting HIV Prevention Drug, Lenacapavir

 

By Samuel Mbewe

Lusaka, Friday, November 7, 2025 — The Zambian government has announced the registration of a new long-acting injectable antiretroviral drug for HIV prevention, marking a major milestone in the country’s ongoing fight against HIV and AIDS.

Health Minister Dr. Elijah Muchima revealed that the Zambia Medicines Regulatory Authority (ZAMRA) has officially approved Lenacapavir, a breakthrough drug that will be administered once every six months. More than 44,000 doses have already been secured and will be made available to the public free of charge.

Speaking during a press briefing in Lusaka, Dr. Muchima hailed the development as “a significant step forward in our efforts to curb new HIV infections and protect vulnerable populations.” He noted that Zambia continues to record approximately 30,000 new HIV infections annually, with adolescent girls and young women remaining the most affected group.

“This innovation offers hope for a future where HIV prevention is more accessible, convenient, and effective,” Dr. Muchima said.

Meanwhile, the Minister disclosed that nine districts across the country have been affected by an ongoing cholera outbreak, with 525 cases reported since August this year. Health authorities are scaling up response measures, including intensified surveillance, community sensitization, and provision of clean water and sanitation facilities.

Dr. Muchima urged the public to remain vigilant and adhere to hygiene guidelines to prevent further spread of cholera, while expressing optimism that the Ministry’s rapid response teams will bring the situation under control.

The introduction of Lenacapavir adds to Zambia’s growing portfolio of HIV prevention strategies, reinforcing the government’s commitment to achieving the UNAIDS 95-95-95 targets and ultimately ending AIDS as a public health threat by 2030.